Malate, a natural inhibitor of 6PGD, improves the efficacy of chemotherapy in lung cancer

The importance of cellular metabolic reprogramming in cancer has attracted considerable attention in recent years [1]. Accumulating evidence indicates that tumor-associated genes [2], cellular microenvironment [3,4], transcription factors [5], and non-coding RNAs [6], as well as mutations in metabolic enzymes themselves or changes in the activity of protein metabolic regulators [7,8], can lead to metabolic reprogramming of tumor cells. Many study have described energy reprogramming events as a cancer hallmark that enable cancer cells to survive, suggesting that metabolic enzymes are attractive molecular targets for the development of cancer therapies [9 –11].

Source: Lung Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Mingming Sun, Qi Feng, Qi Yan, Huifang Zhao, Haiyan Wang, Shuai Zhang, Changliang Shan, Shuangping Liu, Jiyan Wang, Hongyan Zhai Source Type: research